mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial

Advanced Esophageal Carcinoma Clinical Trial

Status Recruiting

Clinical Trial Summary

There are few studies about 2nd line treatment in advanced esophageal carcinoma(AEC), some showed that irinotecan may be effective. The investigators previous study has shown the efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study, the investigators would like to observe the efficacy and safety of Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01044420
Study type	Interventional
Source	Peking University
Contact	zhang xiaodong, MD
Phone	86-01-88196175
Email	zxd0829@yahoo.com.cn
Status	Recruiting
Phase	Phase 2
Start date	May 2009
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01486992` - mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus	Phase 2
Completed	`NCT02023593` - FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma	Phase 2
Active, not recruiting	`NCT04491942` - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	Phase 1